

CrossMark
click for updatesCite this: *RSC Adv.*, 2017, 7, 4167

Aβ_{1–42} C-terminus fragment derived peptides prevent the self-assembly of the parent peptide†

Sunil Bansal,^a Indresh Kumar Maurya,^b Kitika Shenmar,^a Nitin Yadav,^c
Chaitanya Kumar Thota,^c Vinod Kumar,^d Kulbhushan Tikoo,^d
Virander Singh Chauhan^c and Rahul Jain^{*a}

In an attempt to design Aβ aggregation inhibitors to combat Alzheimer's disease, herein we report a full peptide scan performed on a pentapeptide fragment (Aβ_{38–42}) derived from the C-terminus of Aβ_{1–42} peptide. More than thirty new peptides were synthesized and tested for their inhibition activity towards Aβ self-assembly. In the cell viability assay, when co-incubated with Aβ, three peptides were found to completely prevent the toxicity induced by Aβ aggregation. Most active pentapeptides were also studied by ThT fluorescence assay and the results were well correlated to the MTT study. The inhibition potential of a pentapeptide (**15**) was further confirmed by CD spectroscopy and transmission electron microscopy.

Received 4th November 2016
Accepted 19th December 2016

DOI: 10.1039/c6ra26295c

www.rsc.org/advances

Alzheimer's disease (AD), first reported by Alois Alzheimer in 1906,¹ is manifested by the abnormal misfolding of proteins, amyloid-β (Aβ) and tau.² An alarming number of patients, 44 million currently and set to triple by 2050, would create challenges for society on medical and economical fronts.³ Although a number of factors have been suggested to play a role in the etiology of AD,⁴ deposition of neuritic plaques due to the accumulation of Aβ have been the most widely accepted phenomenon.⁵

Acetylcholinesterase inhibitors such as tacrine, donepezil, rivastigmine and galantamine, and *N*-methyl-D-aspartate (NMDA)-receptor antagonist memantine were among the first drugs approved by FDA, however none could prevent or reverse the disease progression.⁶ Since then a number of other strategies such as secretase inhibitors,^{7–10} immunotherapy,^{11,12} metal chelators,^{13,14} tau aggregation regulators¹⁵ have been explored. However, out from more than two hundred molecules tested in

the clinical trials from 2002–12, only one (memantine) is approved as a drug in 2003. Also, the therapeutics that are currently being tested in clinical trials, don't offer much hope. Due to low efficacy or side effects, a large number of promising candidates couldn't proceed beyond phase II, and very few progressed to the phase III clinical trials.

Aβ is known to play positive modulatory role in memory and neurotransmission,¹⁶ hence, the inhibition of Aβ aggregation, is currently being investigated.^{17,18} Reported to inhibit Aβ aggregation, a number of small molecules have reached in clinical trials.^{19,20} A number of studies have shown that modified fragments of Aβ inhibit the aggregation of parent peptide specifically.^{21–26} PPI-1019, a modified pentapeptide derivative of fragment Aβ_{17–21}, has been tested up to phase II clinical trials.²⁷ Similarly, *N*-methylated pentapeptide, SEN-606 has reached in pre-clinical developmental phases.

Since hydrophobic interactions are known to play a significant role in protein misfolding,²⁸ and considering the importance of the peptide fragments in their specific binding with the main peptide chain, a number of Aβ aggregation inhibitors derived from the hydrophobic C-terminus of Aβ were reported. Fragments Aβ_{31–42} and Aβ_{39–42} were found to inhibit Aβ aggregation significantly.²⁹ In a study, poly-*N*-methylated hexapeptides based on Aβ_{32–37} were reported as efficient inhibitors of Aβ self-assembly.³⁰ We reported a hexapeptide based on the Aβ_{32–37} fragment that mitigate Aβ toxicity completely at sub-micromolar concentrations.³¹ Despite the current focus on the C-terminus of Aβ, the region still remains relatively less explored. In order to scrutinize the C-terminus region, we performed a full peptide scan on a C-terminus pentapeptide fragment, Aβ_{38–42}. About 32 new peptides were synthesized by Fmoc solid phase peptide synthesis protocol. All amino acids of the pentapeptide fragment were substituted by physico-chemically

^aDepartment of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Sector 67, S. A. S. Nagar, Punjab 160 062, India. E-mail: rahuljain@niper.ac.in; Fax: +91 172 2214692; Tel: +91 172 2292024

^bDepartment of Microbial Biotechnology, Panjab University, Sector 14, Chandigarh, 160 014, India

^cInternational Center for Genetic Engineering and Biotechnology, Aruna Asif Ali Marg, New Delhi, 110 067, India

^dDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Sector 67, S. A. S. Nagar, 160 062, Punjab, India

† Electronic supplementary information (ESI) available: Synthesis and purification methods, characterization data and, HRMS and HPLC chromatograms of few representative peptides. General method, assay and statistical calculations for the MTT cell viability and thioflavin T fluorescence assay, circular dichroism and transmission electron microscopy. Bar graph showing cytotoxicity profile of peptides **6**, **9**, **15** and, CD spectra of peptides **6** and **29** alone, and a zoomed section of CD spectrum of peptide **15** are provided in ESI. See DOI: 10.1039/c6ra26295c


analogous amino acid residues. Moreover, amino acids such as proline (Pro) and α -aminoisobutyric acid (Aib) were chosen because of their β -sheet breaking properties. Scheme 1 shows the general route for the synthesis of peptides on Wang resin.

Since it is well known that protein misfolding is preceded by intramolecular as well as intermolecular interactions between the monomer units, the synthesized pentapeptide derivatives of fragment $A\beta_{38-42}$ are supposed to exhibit high affinity to specifically interact with full-length $A\beta$ peptide. MTT assay was performed to evaluate the newly synthesized pentapeptides for the inhibitory effects against $A\beta_{1-42}$ aggregation and toxicity using PC-12 cells. Cell viability data for all the synthesized pentapeptides and the conversion in percentage inhibition of $A\beta$ aggregation have been shown in Table 1. The lead peptide (**1**, Gly-Val-Val-Ile-Ala) previously reported to prevent $A\beta_{1-42}$ toxicity by 70% when taken in ten-fold excess, was observed to exhibit significant activity in this study as well.³⁰ In the cell viability assay, peptide **1** reduced the $A\beta_{1-42}$ toxicity by 43% at 10 μ M and 65% at 20 μ M. Among the newly synthesized pentapeptide analogues, four peptides (**6**, Pro-Val-Val-Ile-Ala), (**9**, Gly-Gly-Val-Ile-Ala), (**15**, Gly-Phe-Val-Ile-Ala), and (**21**, Gly-Val-Aib-Ile-Ala) were found to prevent $A\beta_{1-42}$ -induced toxicity in the range of 90–100%. Cell samples treated with premonomerized $A\beta_{1-42}$ (2 μ M), showed a viability of about 70% relative to untreated cells (control, taken as 100%). However, in the presence of peptides **6** (10 μ M), **9** (20 μ M), and **15** (20 μ M), incubated along with $A\beta_{1-42}$, no loss of cell viability was observed. While, in the presence of the peptide **1**, only 89.5% cells were observed to be viable. In the co-presence of peptide **21** (10 μ M), about 97% cells were viable. Also, in the presence of peptides **13** (Gly-Pro-Val-Ile-Ala, 20 μ M), **14** (Gly-Aib-Val-Ile-Ala, 20 μ M), and **29** (Gly-Val-Val-Ile-Gly, 2 μ M), about 88%, 93.4%, and 89.5% cells were observed to be viable, respectively. Table 1 shows the cell viability values of the control (untreated cells) and, PC-12 cells treated with $A\beta$, with and without the presence of pentapeptides. Cell viability values were correspondingly converted into the percentage inhibition values of $A\beta$ toxicity.

Seven other pentapeptides **18** (Gly-Val-Leu-Ile-Ala), **19** (Gly-Val-Ile-Ile-Ala), **23** (Gly-Val-Val-Val-Ala), **24** (Gly-Val-Val-Ala-Ala), **27** (Gly-Val-Val-Aib-Ala), **28** (Gly-Val-Val-Phe-Ala), and

33 (Gly-Val-Val-Ile-Phe) showed moderate inhibition (21–50%) of $A\beta_{1-42}$ toxicity while rest of the peptides did not show any inhibition activity. Pentapeptides **6**, **9**, and **15** showing complete protection for PC-12 cells against $A\beta_{1-42}$ aggregation related toxicity were also tested against shorter and relatively lesser aggregating peptide $A\beta_{1-40}$. However, none of the peptides showed inhibition potential towards $A\beta_{1-40}$ toxicity in PC-12 cells (data not shown). The cell viabilities did not improve when the peptides **6**, **9** or **15** were incubated with $A\beta_{1-40}$ indicating their inefficiency towards attenuation of $A\beta_{1-40}$ assembly. Fig. 1 represents effects of the most active pentapeptides on the restoration of cell viabilities against the toxicity of $A\beta_{1-42}$ peptide.

In ThT assay, significant reduction in the ThT fluorescence was observed when the pentapeptides **6**, **9**, **14**, **15** or **21**, were co-incubated with the monomeric $A\beta_{1-42}$ peptide. Fig. 2A shows the bar graph representation of the relative fluorescence exhibited by ThT when incubated with $A\beta_{1-42}$ alone, and plus the inhibitor pentapeptides. In the ThT assay, reporting % inhibition of $A\beta_{1-42}$ along with RFU values provide better correlation of results. To convert the RFU values into % inhibition values, we also determined and reported RFU values of ThT alone. Relative to blank wells, the enhanced fluorescence shown by $A\beta_{1-42}$ sample alone was taken as 100% and RFU values were calculated for the dye alone and samples containing inhibitor peptides co-incubated with $A\beta_{1-42}$. ThT incubated alone (control) exhibited a RFU of nearly 27%. It was observed that the RFU values in the presence of the inhibitor peptides were similar to that of the control. For example, in the presence of the peptides, **6**, **9**, and **15**, RFU values of 28.5%, 27%, and 27% were observed at 10, 20, and 20 μ M, respectively. Similarly, samples containing **14** and **21** showed RFU of 34.3% and 49.7% at 20 and 10 μ M, respectively (Table T1, ESI†). Reduction in ThT fluorescence in the co-presence of pentapeptides **6**, **9**, **14**, **15** or **21** with $A\beta_{1-42}$ clearly indicates the inhibition of self-assembly of $A\beta_{1-42}$ and provides support to the results obtained in the MTT viability assay. Similar to the MTT assay, none of the tested pentapeptides showed inhibitory activity against the shorter form of amyloid peptide ($A\beta_{1-40}$) in the ThT assay (data not shown). The RFU values remained close to that of $A\beta_{1-40}$ alone, indicating the presence of aggregates and the inefficiency of the peptides to inhibit the aggregation of $A\beta_{1-40}$ peptide. However, the inhibitor peptide **6** was found to reduce the aggregation of 11-residue $A\beta$ peptide fragment ($A\beta_{25-35}$) by 98%, while the other four pentapeptides (**9**, **14**, **15** and **21**) didn't show any significant activity (Fig. 2B, Table T2, ESI†). The control exhibited RFU as 57%, and in the co-presence of peptide **6** along with $A\beta_{25-35}$, RFU value of 57.7% was observed. Using the ThT fluorescence measurement assay, we also studied the pentapeptide **15** in a time-dependent manner against the $A\beta_{1-42}$ aggregation-mediated fluorescence. The peptide **15** was incubated with the $A\beta_{1-42}$ peptide and fluorescence was measured at regular intervals for a total duration of 168 h. As shown in Fig. 3, in the absence of **15**, when $A\beta_{1-42}$ was aged alone with ThT dye, there was a dramatic enhancement in the fluorescence indicating the aggregation of $A\beta_{1-42}$ peptide. The fluorescence reached a plateau at about 120 h. The enhancement in



Scheme 1 Synthesis of peptides exemplified by **6**. Reaction conditions: (i) 20% piperidine in DMF, 15 min; (ii) Fmoc-Ile-OH, TBTU, DIEA, DMF, 2.5 h; (iii) Fmoc-Val-OH, TBTU, DIEA, DMF, 2.5 h; (iv) Fmoc-Val-OH, TBTU, DIEA, DMF, 2.5 h; (v) Fmoc-Pro-OH, TBTU, DIEA, DMF, 2.5 h; (vi) TFA, TIPS, H_2O , 2.5 h.



Table 1 Cell viabilities and inhibition (%) of A β_{1-42} toxicity by the synthesized peptides

No.	Sequence Peptides	Tested concentration range of pentapeptides					
		Cell viability			Inhibition ^a (%) of A β_{1-42} (2 μ M)		
		20 μ M	10 μ M	2 μ M	20 μ M	10 μ M	2 μ M
1	Gly-Val-Val-Ile-Ala	89.5	82.9	73.6	65.0	43.0	12.0
2	Val-Val-Val-Ile-Ala	71.5	70.0	70.0	5.0	0	0
3	Ala-Val-Val-Ile-Ala	70.0	70.0	70.0	0	0	0
4	Leu-Val-Val-Ile-Ala	70.6	72.1	70.0	2.0	7.0	0
5	Ile-Val-Val-Ile-Ala	70.0	70.0	70.0	0	0	0
6	Pro-Val-Val-Ile-Ala	72.1	100	88.0	7.0	100	60.0
7	Aib ^b -Val-Val-Ile-Ala	70.0	70.0	70.3	0	0	1.0
8	Phe-Val-Val-Ile-Ala	70.0	70.0	70.0	0	0	0
9	Gly-Gly-Val-Ile-Ala	100	85.0	84.7	100	50.0	49.0
10	Gly-Ala-Val-Ile-Ala	70.0	70.0	70.0	0	0	0
11	Gly-Leu-Val-Ile-Ala	70.0	70.0	70.3	0	0	0
12	Gly-Ile-Val-Ile-Ala	70.0	70.0	72.1	0	0	7.0
13	Gly-Pro-Val-Ile-Ala	88.0	82.0	70.3	60.0	40.0	1.0
14	Gly-Aib-Val-Ile-Ala	93.4	75.1	73.6	78.0	17.0	12.0
15	Gly-Phe-Val-Ile-Ala	100	84.7	73.3	100	49.0	11.0
16	Gly-Val-Gly-Ile-Ala	70.0	70.0	70.3	0	0	0
17	Gly-Val-Ala-Ile-Ala	70.0	70.0	70.0	0	0	0
18	Gly-Val-Leu-Ile-Ala	78.1	77.2	74.8	27.0	24.0	16.0
19	Gly-Val-Ile-Ile-Ala	78.4	84.4	84.4	28.0	48.0	48.0
20	Gly-Val-Pro-Ile-Ala	72.7	71.2	71.8	9.0	4.0	6.0
21	Gly-Val-Aib-Ile-Ala	88.3	97.0	85.6	61.0	90.0	52.0
22	Gly-Val-Phe-Ile-Ala	71.8	70.0	70.0	6.0	0	0
23	Gly-Val-Val-Val-Ala	79.6	82.3	82.0	32.0	41.0	40.0
24	Gly-Val-Val-Ala-Ala	81.4	80.8	78.7	38.0	36.0	29.0
25	Gly-Val-Val-Leu-Ala	71.5	70.0	70.0	5.0	0	0
26	Gly-Val-Val-Pro-Ala	70.0	70.0	71.2	0	0	4.0
27	Gly-Val-Val-Aib-Ala	79.0	74.5	73.9	30.0	15.0	13.0
28	Gly-Val-Val-Phe-Ala	76.9	75.7	74.5	23.0	19.0	15.0
29	Gly-Val-Val-Ile-Gly	74.5	82.3	89.5	15.0	41.0	65.0
30	Gly-Val-Val-Ile-Val	74.8	73.3	72.7	16.0	11.0	9.0
31	Gly-Val-Val-Ile-Leu	70.4	72.0	70.0	4.0	1.0	0
32	Gly-Val-Val-Ile-Ile	70.6	70.0	72.1	2.0	0	7.0
33	Gly-Val-Val-Ile-Phe	84.7	82.6	82.3	49.0	42.0	41.0
Control		100					
A β_{1-42}		70.0					

^a Each experiment was performed in triplicates ($n = 3$). ODs (absorbance) of samples with untreated cells were set to 1. Taking the cell viability of untreated cells as 100, percentage cell viabilities were calculated for the cell samples treated with A β alone or plus the test peptides. Subsequently, the percentage inhibition of A β toxicity by each test peptide was calculated by using the formula: $100 \times [\text{OD}_{570} (\text{test peptide with A}\beta_{1-42}) - \text{OD}_{570} (\text{A}\beta_{1-42})] / [\text{OD}_{570} (\text{control}) - \text{OD}_{570} (\text{A}\beta_{1-42})]$. Blank ODs were subtracted from each sample OD and the triplicate ODs were averaged. In a subset of triplicate wells, ODs did not deviate much from the mean and SD ranged between 1.68 and 4.40. ^b Aib denotes aminoisobutyric acid.

fluorescence observed in the A β_{1-42} sample relative to control (ThT alone) at saturation point was considered as 100%, and the relative fluorescence (RFU) values were calculated for the inhibitor peptide 15 co-incubated with the aggregating A β_{1-42} peptide. The fluorescence shown by the blank wells were subtracted from the test samples. In the presence of peptide 15, fluorescence measurements showed RFU of 62% at 12 h (Fig. 3).

At 24 h, peptide 15 co-incubated samples showed only a relative fluorescence of only 15%, while RFU values of 8%, 13% and 6%, were observed at the end of 72, 120, and 168 h, respectively. Summarily, in the presence of peptide 15, very low RFU values (6–15%) were observed especially once the fluorescence reached its saturation point (24–168 h). Since, the fluorescence values correspond to the aggregation state of the A β

peptide, retardation in the fluorescence indicates the ability of peptide 15 to interfere with the A β_{1-42} peptide self-assembly.

CD spectroscopy was performed to study the inhibitory effects of pentapeptide 15 on the conformational transition of A β_{1-42} peptide. Monomeric A β_{1-42} incubated alone, showed a conformational change from random coil towards an increase in the β -sheet content indicated by the shift from a sharp minima at 198 nm to broad negative peak at 217–218 nm (Fig. 4). At the start, A β_{1-42} occupied a conformation as a mixture of 61.8% of random coil, 28.7% β -turn and only 9.5% of β -sheet, while at the end of 12 h of incubation, A β_{1-42} exhibited about 47.1% of β -sheet component, with the random coil being only 42.3%. However, after 12 h ($t_{12 \text{ h}}$) of co-incubation with peptide 15, A β_{1-42} exhibited only 16.2% of β -sheet conformation and 59% random



coil form (Fig. 4). Thus the prevention of conformational transition towards β -sheet content is a direct indication of the inhibitory activity of the pentapeptide 15.

Since the secondary structural analysis presented by CD spectroscopy is a good indicator of the peptide conformational state, a study was performed to investigate the conformational behaviour of peptides 6 and 29 exhibiting inverse relationship of inhibition activity with increasing concentration (10-fold to $A\beta_{1-42}$) in the MTT assay. Upon deconvolution of the CD spectra, it was observed that the peptide 6 showed an enhancement in the β -sheet content from an initial 13.1% to 46.6% at the end of incubation period. As shown in Fig. S3 (ESI[†]), the minima in the curve at 217 nm deepens at the 12 h ($t_{12\text{ h}}$) of incubation, relative to the $t_{0\text{ h}}$ curve. At the same, time the random coil content decreased from 59.9% to 43.1%. Similarly, pentapeptide 29 also showed an increase in the β -sheet content during incubation (Fig. S4, ESI[†]). Starting from an initial value of 14%, 44.4% of peptide was observed to be in β -sheet conformation at the end of incubation period while a decrease in the random coil form was observed from 58.3% at $t_{0\text{ h}}$ to 45.5% at $t_{12\text{ h}}$. The self-aggregation exhibited by these peptides also explains their higher activity at low concentration and *vice versa*. We envision that when taken at 10-fold excess, the peptides themselves aggregate, and thus may not be available to interact with the aggregating $A\beta$ peptides in the solution. Hence, enhancement in the β -sheet content of the peptides 6 and 29 as shown by CD spectroscopy provides support to the pattern of results observed in the MTT and ThT.




Fig. 1 Effects of pentapeptides 1, 6, 9, 13, 14, 15, 21, and 29 on the $A\beta_{1-42}$ -induced cytotoxicity in PC-12 cells. Cells were treated with $A\beta_{1-42}$ (2 μM) alone or $A\beta_{1-42}$ plus 1, 6, 9, 13, 14, 15, 21, and 29 (2–20 μM) for 6 h, after which their ability to reduce the MTT was measured. Control represents the untreated cell samples while $A\beta_{1-42}$ bar represents the cell viability upon treatment with $A\beta_{1-42}$ peptide. Subsequent bars represent the cell samples where the pentapeptides 1, 6, 9, 13, 14, 15, 21, or 29 were co-incubated along with $A\beta_{1-42}$ peptide. Viabilities are expressed as percentage of untreated cells (control). Error bars represent mean \pm standard deviation (SD, $n = 3$). Data were analyzed by one way ANOVA test followed by Dunnett's multiple comparison test ($^{\$}p < 0.05$, $^{\#}p < 0.01$, $^*p < 0.001$, vs. $A\beta_{1-42}$) using software (Graph pad Prism, ISI, San Diego, CA).




Fig. 2 Effects of the pentapeptides 6, 9, 14, 15 and 21 on (A) $A\beta_{1-42}$ and (B) $A\beta_{25-35}$ aggregation-mediated ThT fluorescence. Control represents the dye alone while $A\beta_{1-42}$ and $A\beta_{25-35}$ represents the $A\beta$ peptides incubated along with the dye. Subsequent bars represent the inhibitor peptides (indicated by numbers), co-incubated with the corresponding $A\beta$ peptides and ThT dye. Error bars represent mean \pm SD ($n = 3$). Data were analyzed by one way ANOVA test followed by Dunnett's multiple comparison test ($^{\$}p < 0.05$, $^{\#}p < 0.01$, $^*p < 0.001$, vs. control) using software (Graph pad Prism, ISI, San Diego, CA).

Finally, visual investigation of the inhibitory effects of peptide 15 on the morphology and abundance of $A\beta_{1-42}$ fibrils was performed by high resolution transmission electron microscopy (HR-TEM). Shapes and appearance of the fibrils were also examined using scanning transmission electron microscopy (STEM). Peptide 17 observed as inactive in the MTT cell viability assay was selected as a negative control. In the control sample when monomeric $A\beta_{1-42}$ was incubated alone, we observed long, rod like cylindrical fibrils with no ends in successive images (Fig. 5A, HRTEM and Fig. 6A, STEM). However, no such fibrils were observed when the peptide 15 was co-incubated with the $A\beta_{1-42}$ peptide (Fig. 5B, HRTEM and Fig. 6B, STEM).

Upon incubating peptide 15 alone under similar conditions, no aggregates of fibrillar morphology were observed. Instead very small globular structures were seen (Fig. 5C, HRTEM and Fig. 6C, STEM). An extensive network of very fine thread-like fibrils was observed when the peptide 17 was co-incubated with $A\beta_{1-42}$ peptide (Fig. 5D, HRTEM and Fig. 6D, STEM). Though the thickness of the fibrils was much lesser than that




Fig. 3 Effects of pentapeptide 15 on $A\beta_{1-42}$ peptide aggregation, studied in a time-dependent manner for 7 days. Red line shows the $A\beta_{1-42}$ peptide aged alone. Green line represents $A\beta_{1-42}$ peptide co-incubated with peptide 15. Error bars represent mean \pm SD ($n = 3$). Data were analyzed by t -test ($^*p < 0.001$, vs. $A\beta_{1-42}$) using software (Graph pad Prism, ISI, San Diego, CA).






Fig. 4 CD spectrum shows the inhibitory effects of pentapeptide 15 on the conformation of $A\beta_{1-42}$. Conformational transitions of $A\beta_{1-42}$ at t_0 h and t_{12} h are represented by black and red spectral lines, respectively. The clear deepening of red curve after 12 h of incubation represents the increase in β -sheet structure relative to at zero hours. However, blue curve shows no such minima at 217 nm, when $A\beta_{1-42}$ peptide was co-incubated with peptide 15 at 12 h, indicates the absence of any β -sheet aggregates.

observed in control ($A\beta$ alone), the complex of fibrils was much more extensive. This probably might have resulted by the endwise association of $A\beta$ monomers in the presence of peptide 17. The peptide 17 was also seen to form large clusters of amorphous aggregates when incubated alone under similar conditions (Fig. 5E, HRTEM and Fig. 6E, STEM). Constituted by highly hydrophobic amino acid residues, the plausible self-aggregation might be the reason for the inactivity of pentapeptide 17. Therefore, the absence of $A\beta_{1-42}$ fibrils as observed in the electron microscopy study provides further support for the inhibitory activities of pentapeptide 15.

Being a part of the hydrophobic C-terminus of $A\beta_{1-42}$, the most active pentapeptides 6, 9 and 15 were tested for the self-aggregation related toxicity by MTT cell assay. As described earlier for MTT viability procedure, sampling and assay was




Fig. 5 TEM analysis showing the effects of inhibitor peptide 15 and the inactive peptide 17 on aggregation of $A\beta_{1-42}$ peptide. $A\beta_{1-42}$ was incubated, (A) alone (B) with inhibitor peptide, 15 (D) with the inactive peptide, 17. Images (C) and (E) correspond to peptides 15 and 17, incubated alone, respectively. The scale bar shows 0.2 μ m.




Fig. 6 STEM analysis showing the effects of inhibitor peptide 15 and the inactive peptide 17, on aggregation of $A\beta_{1-42}$ peptide. $A\beta_{1-42}$ was incubated, (A) alone (B) with inhibitor peptide, 15 (D) with the inactive peptide, 17. Images (C) and (E) correspond to peptides 15 and 17, incubated alone, respectively. The scale bar shows 500 nm.

adopted for the activity study. The peptides did not show any toxic effect on the cells under study at the highest tested concentration of 20 μ M (Fig. S1, ESI[†]). All sample wells containing peptides 6, 9 and 15 showed MTT reduction quite similar to that of untreated cells (control).

Considering the activity of the lead peptide (1, 65% inhibition at 20 μ M) as the reference, inhibition potential of the newly synthesized pentapeptides was correlated with the replacement amino acid residues and structure–activity relationship was established (Fig. 7). The replacement of the first amino acid residue (Gly₃₈), by proline resulted in a very efficient $A\beta_{1-42}$ polymerization inhibitor. The resulting peptide (Pro–Val–Val–Ile–Ala, 6) prevented the $A\beta_{1-42}$ aggregation completely. The substitutions at the Val₃₉ residue yielded the best inhibitor peptides. The peptide wherein Val₃₉ was replaced with proline (Gly–Pro–Val–Ile–Ala, 13) showed 60% inhibition of $A\beta_{1-42}$ fibrillation; the replacement by Aib afforded a peptide (Gly–Aib–Val–Ile–Ala, 14) with significant (78%) inhibition potential. Two more highly promising peptides were discovered by modification at this position with Gly (Gly–Gly–Val–Ile–Ala, 9) and Phe (Gly–Phe–Val–Ile–Ala, 15) residues, exhibiting 100% inhibition




Fig. 7 Structure activity relationship of pentapeptides.



of A β _{1–42} aggregation. The peptide synthesized by replacing Val₄₀ with Aib (Gly–Val–Aib–Ile–Ala, **21**) showed 90% inhibitory activity. Lastly, most of the replacements at the next two amino acids (Ile₄₁ and Ala₄₂) resulted in the peptides that were only moderately active, showing a maximum of 40% and 65% inhibition, respectively. Conclusively, the substitutions, specifically at the residues, A β ₃₉→Pro/Aib and A β ₄₀→Pro/Aib, have resulted in peptides with significant inhibition potential towards the A β _{1–42} peptide self-assembly.

Conclusions

More than thirty new peptides were synthesized by performing a full peptide scan on fragment A β _{38–42} of A β _{1–42}. The synthesized pentapeptides were bio-evaluated for their inhibitory activity against the aggregation of A β peptides. Three of the best peptides identified in the initial screening by MTT assay, showing significant to complete reduction in amyloid toxicity were taken forward for further studies. ThT fluorescence assay results were found to be in good agreement with the cell-based MTT assay. CD spectral analysis and electron microscopy further provided confirmative supports to the observations. As observed in several studies earlier, the selective activity of pentapeptides (**6**, **9**, **15**) against the longer form (A β _{1–42}) than shorter amyloid peptide (A β _{1–40}) suggests their probable interactions with the last two residues (Ile₄₁ and Ala₄₂) of hydrophobic C-terminus of A β _{1–42}. Further, it is well known that hydrophobic interactions play an important role in peptide aggregation. Two best peptides [GGVIA (**9**) and GFVIA (**15**)] consist of only hydrophobic amino acid residues, therefore it is very probable that the interaction of pentapeptide fragments with hydrophobic C-terminus of A β may outrace that between A β monomers and intercalate between them, leading to the formation of non-fibrillar structures. Another active peptide (PVVIA, **6**) with an anti- β -sheet residue (proline) probably interact with A β and prevent the formation of cross- β -sheet structures, which is a pre-requisite for A β aggregation. We envision that the peptides discovered herein by peptide scan approach, may, with further modifications, yield promising therapeutics to reach to advanced studies for treatment against Alzheimer's disease.

Abbreviations

CD	Circular dichroism
DIEA	<i>N,N</i> -Diisopropylethylamine
FDA	Food and drug administration
Fmoc	9-Fluorenylmethoxycarbonyl
HPLC	High-performance liquid chromatography
HR-TEM	High resolution transmission electron microscopy
MTT	3-(4,5-Dimethylthiazol-2-yl)-2'-5-diphenyltetrazolium] bromide
OD	Optical density
PC-12 cells	Pheochromocytoma-12 cells
RFU	Relative fluorescence unit

SD	Standard deviation
STEM	Scanning transmission electron microscopy
TBTU	<i>O</i> -(Benzotriazol-1-yl)- <i>N,N,N'</i> , <i>N'</i> -tetramethyluronium tetrafluoroborate
TIPS	Triisopropylsilylether
ThT	Thioflavin T

Acknowledgements

Sunil Bansal thanks the Council of Scientific and Industrial Research (CSIR), New Delhi, India, for the award of senior research fellowship.

Notes and references

- 1 A. Alzheimer, R. A. Stelzmann, H. N. Schnitzlein and F. R. Murtagh, *Clin. Anat.*, 1995, **8**, 429–431.
- 2 G. S. Bloom, *JAMA Neurol.*, 2014, **71**, 505–508.
- 3 Dementia and risk reduction: an analysis of protective and modifiable factors, Alzheimer's disease international, World Alzheimer Report, 2014, <http://www.alz.co.uk/research/WorldAlzheimerReport2014.pdf>.
- 4 T. Jiang, J. T. Yu and L. Tan, *Curr. Alzheimer Res.*, 2013, **10**, 852–867.
- 5 S. Sadigh-Eteghad, B. Sabermarouf, A. Majdi, M. Talebi, M. Farhoudi and J. Mahmoudi, *Med. Princ. Pract.*, 2015, **24**, 1–10.
- 6 E. D. Roberson and L. Mucke, *Science*, 2006, **314**, 781–784.
- 7 B. Vellas, O. Sol, P. Snyder, P. Ousset, R. Haddad, M. Maurin, J.-C. Lemarié, L. Désiré and M. Pando, *Curr. Alzheimer Res.*, 2011, **8**, 203–212.
- 8 <https://Merck.ClinicalTrials.gov> [website on the Internet] Bethesda, MD, US national library of medicine, 2013, Accessed November 22, 2013, efficacy and safety trial of MK-8931 in participants with prodromal Alzheimer's disease (MK-8931-019) (APECS) updated November 19, 2013. Available from, <http://www.clinicaltrials.gov/ct2/show/NCT01953601?term=MK-8931&rank=3>, NLM identifier: NCT01953601.
- 9 R. S. Doody, R. Raman, M. Farlow, T. Iwatsubo, B. Vellas, S. Joffe, K. Kieburtz, F. He, X. Sun, R. G. Thomas and P. S. Aisen, *N. Engl. J. Med.*, 2013, **369**, 341–350.
- 10 G. K. Wilcockemail, S. E. Black, A. H. Balch, D. A. Amato, A. P. Beelen, L. S. Schneider, R. C. Green, E. A. Swabb and K. H. Zavitz, *Alzheimer's Dementia*, 2009, **5**, 86.
- 11 J. M. Orgogozo, S. Gilman, J. F. Dartigues, B. Laurent, M. Puel, L. C. Kirby, P. Jouanny, B. Dubois, L. Eisner, S. Flitman, B. F. Michel, M. Boada, A. Frank and C. Hock, *Neurology*, 2003, **61**, 46–54.
- 12 G. Munch and S. R. Robinson, *J. Neural Transm.*, 2002, **109**, 1081–1087.
- 13 C. W. Ritchie, A. I. Bush, A. Mackinnon, S. Macfarlane, M. Mastwyk, L. MacGregor, L. Kiers, R. Cherny, Q. X. Li, A. Tammer, D. Carrington, C. Mavros, I. Volitakis, M. Xilinas, D. Ames, S. Davis, K. Beyreuther, R. E. Tanzi and C. L. Masters, *Arch. Neurol.*, 2003, **60**, 1685–1691.



- 14 L. Lannfelt, K. Blennow, H. Zetterberg, S. Batsman, D. Ames, J. Harrison, C. L. Masters, S. Targum, A. I. Bush, R. Murdoch, J. Wilson and C. W. Ritchie, *Lancet Neurol.*, 2008, **9**, 779–786.
- 15 Safety and efficacy study evaluating TRx0237 in subjects with mild-to-moderate Alzheimer's disease, <https://www.clinicaltrials.gov/ct2/show/NCT01689233>.
- 16 D. Puzzo, L. Privitera, E. Leznic, M. Fa, A. Staniszewski, A. Palmeri and O. Arancio, *J. Neurosci.*, 2008, **28**, 14537–14545.
- 17 Q. Wang, X. Yu, L. Li and J. Zheng, *Curr. Pharm. Des.*, 2014, **20**, 1223–1243.
- 18 Q. Nie, X.-G. Du and M.-Y. Geng, *Acta Pharmacol. Sin.*, 2011, **32**, 545–551.
- 19 S. Salloway, R. Sperling, R. Keren, A. P. Porsteinsson, C. H. van Dyck, P. N. Tariot, S. Gilman, D. Arnold, S. Abushakra, C. Hernandez, G. Crans, E. Liang, G. Quinn, M. Bairu, A. Pastrak and J. D. Cedarbaum, *Neurology*, 2011, **77**, 1253–1262.
- 20 A. Mahler, S. Mandel, M. Lorenz, U. Ruegg, E. E. Wanker, M. Boschmann and F. Paul, *EPMA J.*, 2013, **4**, 5.
- 21 E. Gazit, *FEBS J.*, 2005, **272**, 5971–5978.
- 22 A. F. Susanne and W. Dieter, *Curr. Pharm. Des.*, 2012, **18**, 755–767.
- 23 A. Esteras-Chopo, M. T. Pastor, L. Serrano and M. Lopez de la Paz, *J. Mol. Biol.*, 2008, **377**, 1372–1381.
- 24 C. Soto, E. M. Sigurdsson, L. Morelli, R. A. Kumar, E. M. Castaño and B. Frangione, *Nat. Med.*, 1998, **4**, 822–826.
- 25 S. Bieler and C. Soto, *Curr. Drug Targets*, 2004, **5**, 553–558.
- 26 C. Soto and L. Estrada, *Subcell. Biochem.*, 2005, **38**, 351–364.
- 27 Safety Study of PPI-1019 in Patients With Mild–Moderate Alzheimer's Disease, 2004, <https://clinicaltrials.gov/ct2/show/NCT00100282>.
- 28 C. Hilbich, B. Kisters-Woike, J. Reed, C. L. Masters and K. Beyreuther, *J. Mol. Biol.*, 1992, **228**, 460–473.
- 29 E. A. Fradinger, B. H. Monien, B. Urbanc, A. Lomakin, M. Tan, H. Li, S. M. Spring, M. M. Condron, L. Cruz, C. W. Xie, G. B. Benedek and G. Bitan, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 14175–14180.
- 30 P. Pratim Bose, U. Chatterjee, C. Nerelius, T. Govender, T. Norström, A. Gogoll, A. Sandegren, E. Göthelid, J. Johansson and P. I. Arvidsson, *J. Med. Chem.*, 2009, **52**, 8002–8009.
- 31 S. Bansal, I. K. Maurya, N. Yadav, C. Thota, V. Kumar, K. Tikoo, V. S. Chauhan and R. Jain, *ACS Chem. Neurosci.*, 2016, **7**, 615–623.

